Slavcev, Mary

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

Fonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 127

Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Moreau, P., Usmani, S. Z., van de Donk, N. W. C. J., Garfall, A. L., Delforge, M., Oriol Rocafiguera, A., Nooka, A. K., Rosiñol, L., Bahlis, N. J., Rodríguez-Otero, P., et al. (2022) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsStatistical Methods in Clinical Trials

Cited by 5

P-265: Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database

Kumar, S., Nair, S., Lin, X., Marshall, A., Slavcev, M., Potluri, R., & Chari, A. (2022) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3

P-237: Real-world treatment patterns and clinical outcomes in patients with triple-class exposed relapsed or refractory multiple myeloma in United States clinical practice

Chari, A., Nair, S., Lin, X., Marshall, A., Slavcev, M., & Kumar, S. (2022) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1